2014

Uppsala University, Sweden

Kjell Öberg, MD, is Professor of Endocrine Oncology at the Medical Faculty of Uppsala University.

He is a specialist in endocrinology and internal medicine. He founded the Department of Endocrine Oncology at Uppsala University Hospital and has 30 years experience in the field of neuroendocrine tumors. He is the chairman of Centre of Excellence of Endocrine Tumors and Vice-chairman of the Department of Endocrine Oncology, University Hospital, Uppsala and Adjunct Professor of Surgery at Vanderbilt University.

Dr. Öberg has pioneered the treatment of carcinoid tumor patients with interferon and somatostatin analogs and developed assays for tumor markers such as Chromogranin A and radiological procedures including specialized PET scans. He is also one of the founders of the European Neuroendocrine Tumor Society.

In 1988 he was the first to describe a genetic deletion in multiple endocrine neoplasia Type 1 (MEN1). Dr. Öberg has given many hundreds of presentations at international meetings and published more than 500 papers within his research field, H-factor 64 and more than 12,000 citations. Also, he is the author of numerous chapters on Carcinoid tumors in several international textbooks.

Dr. Öberg is a member of the Royal Society of Sciences, member of Swedish Society of Medical Research, Honorary member of Finnish Oncology Society, Finnish Endocrine Society and Honorary member of Spanish Neuroendocrine NET-work. Dr. Öberg is Chairman-Elect of ENETS and also a member of the NANETS Advisory Board as well as several other national and international research and scientific boards and many scientific journal review boards.